Ranbaxy Talks Up Monetization Of First To Files Like Lipitor, Diovan, Actos if FDA Issues Stay Foggy; Are Big Launches Imperilled?

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.